Today: 9 June 2026
Rolls-Royce share price in focus: Delta Airbus order and buyback filing tee up London open
29 January 2026
2 mins read

Rolls-Royce share price in focus: Delta Airbus order and buyback filing tee up London open

London, Jan 29, 2026, 07:53 GMT — Premarket

  • Rolls-Royce shares fell 2.6% on Wednesday, dragged down by a softer FTSE 100.
  • Delta has placed an order for 31 Airbus widebodies powered by Rolls-Royce Trent engines, with deliveries scheduled to begin in 2029.
  • Rolls-Royce has repurchased additional shares as part of its £200 million buyback, according to a recent filing.

Rolls-Royce (RR.L) shares could see action at Thursday’s London open following Delta Air Lines’ announcement of a 31-aircraft order for Airbus widebody jets, with deliveries kicking off in 2029. Delta CEO Ed Bastian highlighted that the new planes would “enhance our capabilities and elevate our premium offerings.” Airbus North America chief Robin Hayes added the jets would “power their global growth.” Delta News Hub

For Rolls-Royce, it’s not just about scoring that first engine sale. The real value lies in long-term servicing contracts for large engines, which can stretch over years and become crucial as planes rack up miles on lengthy routes.

This is crucial now since the stock is closely linked to two key factors: civil aerospace demand and shareholder returns. The company has relied heavily on buybacks, repurchasing and canceling its own shares as a clear method of returning cash to investors.

Shares dropped 2.58% Wednesday, closing at 12.08 pounds, lagging the FTSE 100 which fell 0.52%. About 17.3 million shares changed hands, shy of the 50-day average volume of 26.0 million. The stock now sits 7.55% below its 52-week peak of 13.07 pounds, hit on Jan. 14.

Rolls-Royce announced Wednesday that Delta Air Lines placed an order for 30 Trent XWB-84 EP engines and 32 Trent 7000 engines. These will power 15 Airbus A350-900s and 16 Airbus A330neos. The deal includes TotalCare, Rolls-Royce’s long-term support package that tracks engine health and handles maintenance. Rob Watson, president of civil aerospace, called the reorder a “commitment to reliability, durability, and customer success.” Delta TechOps chief John Laughter praised the Trent XWB-84 as a “highly reliable engine in our fleet.” Rolls-Royce

A filing on Thursday revealed that Rolls-Royce repurchased 845,685 shares on Jan. 28, paying between 1,209 and 1,248 pence each. This move is part of its £200 million buyback plan carried out via UBS. The company confirmed it will cancel the shares and has now bought back around 9.6 million shares since the programme started.

Late Tuesday, a regulatory filing revealed that CEO Tufan Erginbilgic and CFO Helen McCabe had incentive plan shares vest on Jan. 26. To cover tax withholding, Erginbilgic sold 4,862 shares, McCabe offloaded 1,880. Erginbilgic kept 5,460 shares from the vesting, while McCabe held onto 2,110, according to the notice.

Rolls-Royce revealed a £200 million interim buyback in December, following a £1 billion buyback completed in November. The company said the new programme kicked off on Jan. 2 and should wrap up by Feb. 24 at the latest. Any larger buyback plans for 2026 will need board approval.

Airbus delivery schedules and airline network strategies will also guide investors. While engine manufacturers secure orders years ahead, their cash flow tends to follow flying hours and maintenance costs as fleets age.

The widebody cycle can shift fast. A drop in long-haul demand, delays in aircraft deliveries, or surprise engine maintenance bills would challenge market expectations and might dampen the investor enthusiasm fueling buybacks.

Rolls-Royce’s 2025 full-year results, due Feb. 26, stand as the next major trigger. Investors will be watching closely for updated guidance, cashflow details, and any moves on shareholder returns.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Seatrium share price slips on SGX as Feb 26 results loom, DolWin 5 arbitration in focus
Previous Story

Seatrium share price slips on SGX as Feb 26 results loom, DolWin 5 arbitration in focus

HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move
Next Story

HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move

Go toTop